Despite the hype surrounding GLP-1 receptor agonists, a significant proportion of patients discontinue treatment after a few months, reducing the chances of long-term benefits.
A recent study out of Laval University finds many foods that are high in sodium and sugar on Canadian shelves are much cheaper than healthier, equivalent options.
Orforglipron, a GLP-1 receptor agonist in tablet form, has proven effective in treating obesity in a phase 3 trial, offering a potential alternative to injectable treatments like Wegovy and Ozempic.
Obesity Canada’s 2025 clinical practice guideline update on pharmacotherapy for obesity management includes recommendations for obesity management in adults with specific co-morbidities.
A study of more than one million adolescents reveals a marked association between a low BMI in adolescence and an increased risk of osteoporosis in adulthood.
